China Cord Blood Corp: (NYSE: CO)

$2.91

0.04 (1.39%)

Volume 135,288

Jun 18 04:01 PM ET

Zacks Rank: 3-Hold

Zacks Rank	Definition	Annualized Return
#1	Strong Buy	26.6%
#2	Buy	18.71%
#3	Hold	10.12%
#4	Sell	4.32%
#5	Strong Sell	2.16%
S&P	500	9.93%

Overview Quote

            Stock Activity
        
		Day Low - High
		2.86 - 2.91
	
		52wk Low - High
		2.21 - 3.20
	
		Previous Close
		2.87
	
		Avg. Volume
		61,097
	
		Industry
		MED-OUTP/HM CRE
	
		Market Cap
		209.52 M
	
		Div - Yield
		0.00 - 0.00
	
		Beta
		0.32
	
		P/E (F1)
		13.67
	
		Current Year Est.
		0.21
	
		Quarterly Earnings ESP 
		NA
	
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

                Premium research
            
		Zacks Rank  Short-Term: 1-3 Months
                                                                
                                                                Zacks #1 Rank Strong Buys
                                                                
                                                            This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                        Zacks Rank
                                                                        Definition
                                                                        Annualized Return
                                                                    
                                                                        #1
                                                                        Strong Buy
                                                                        26.6%
                                                                    
                                                                        #2
                                                                        Buy
                                                                        18.71%
                                                                    
                                                                        #3
                                                                        Hold
                                                                        10.12%
                                                                    
                                                                        #4
                                                                        Sell
                                                                        4.32%
                                                                    
                                                                        #5
                                                                        Strong Sell
                                                                        2.16%
                                                                    
                                                                        S&P
                                                                        500
                                                                        9.93%
                                                                    
Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
                                                        
		3
Hold

		Zacks Recommendation  Long-Term: 6+ Months
                                                                
                                                                All Outperform Rated Stocks
                                                                
                                                            Zacks Recommendations are an excellent predictor of stock price movement over a 6+ month time frame. The recommendations come from the Zacks Equity Research group which combines the Zacks Rank with the insights from their team of over 50 equity analysts. The result is superior long term stock ratings.
The Zacks Recommendations are split into 3 groups: Buy, Hold and Sell. Our Buy recommendations have generated returns of 34.4% in 2006, and 16.69% in 2007. When Zacks Premium members click on the recommendation it will launch them to the Zacks Equity Research report for the stock.    More on these reports below.

                                                                    Difference Between Zacks Rank and Zacks Recommendation

                                                                    Zacks Equity Research Home
Zacks Premium - The only way to get access to Zacks Recommendations
                                                                
		Neutral
	
		Zacks Industry Rank Which industries are set to outperform or underperform the market? You'll find the answer here. We have broken down all industries into over 200 classifications. Then ranked these industries using the most powerful indicator we know (the Zacks Rank). The higher the industry rank, the better the industry should perform in the future. Once you have found an attractive industry then check out the Rank in Industry to find the best stocks within the industry.
When Zacks Premium members click on the Zacks Industry Rank link they will see the full listing of industries and their current rankings.

                                                                About Zacks Industry Rank

                                                                Zacks Industry Rank - All current industry ranks. 

                                                                Zacks Premium - The only way to get access to the Zacks Industry Rank
                                                            
		178 out of 265
	
		Equity Research Report The Zacks Recommendations and Zacks Target Prices are just two of the valuable resources you'll find in the reports created by the Zacks Equity Research group. When Zacks Premium members click on this link they will taken to a page that gives them access to the Zacks Equity Research report for the stock.

                                        Zacks Equity Research Home
                                        Zacks Premium - The only way to get access to Zacks Recommendations
                                    
Updated as of 05/31/2013

		PREMIUM
	
    (  = Change in last 30 days) 
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial 
Zacks Premium Home | Zacks Rank Stock Education

                Key Earnings Data
            
                            P/E (F1)
                            13.67
                        
                            PEG Ratio
                            NA
                        
                            Current Year Est.
                            0.21
                        
                            Current Quarter Estimate
                            0.02
                        
                            Most Accurate Estimate
                            NA
                        
                            Earnings ESP 
                            NA
                        
                            Next Earnings Report Date
                            06-18-2013
                        
                            EPS Last Year
                            0.24
                        
                            Expected Earnings Growth
                            NA
                        
Earnings ESP (Expected Surprise Prediction) is Zacks' proprietary methodology for determining which stocks have the best chance to surprise with their next earnings announcement. The Earnings ESP shows the percentage difference between the Most Accurate Estimate and the Consensus.

            Company Description
        
China Cord Blood Corporation is the first and the largest cord blood banking operator in China in terms of geographical coverage and is the only cord blood bank operator with more than one license (i.e., Beijing and Guangdong). Under the current PRC government regulations, only one licensed cord blood bank operator is permitted to operate in each licensed region and only six licenses has been issued as of today. China Cord Blood Corporation collects umbilical cord blood stem cells from newborn babies, and provides laboratory testing, hematopoietic stem cell processing, and stem cell storage services.   
Full CO Company Report

 Snapshot on CO

NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.

            Interactive Java Charting | Fundamental Charts
        
            <a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="336" height="280" border="0" alt="" /></a>        
Turn Earnings Surprises into quick profits.
 
CO Chart  by YCharts

Earnings Estimates

	Current Qtr (03/2013)	Next Qtr (06/2013)	Current Year (03/2013)	Next Year (03/2014)
Average Estimate	0.02	0.02	0.20	0.21
Number of Estimates	1	1	1	1
Low Estimate	0.02	0.02	0.20	0.21
High Estimate	0.02	0.02	0.20	NA
Year Ago EPS	0.06	0.06	0.28	0.20
EPS Growth	-66.67%	-66.67%	-28.57%	5.00%

More CO Estimates

Average Earnings Estimates for CO

EPS Growth for CO

Industry Analysis

Name	Symbol	Previous Close
CHINA CORD BLD	CO	2.87
ADDUS HOMECARE	ADUS	19.63
HEALTHSOUTH CP	HLS	29.55
LCA-VISION INC	LCAV	3.22
US PHYSICAL THR	USPH	30.16
AMSURG CORP	AMSG	36.21
BRAIN RESOURCE	BRRZY	0.00
DAVITA INC	DVA	130.16
LHC GROUP LLC	LHCG	22.25
QUEST DIAGNOSTC	DGX	62.59

Sector:Medical>> Industry:MED-OUTP/HM CRE

COMPARE TICKER vs. Its Peers

Zacks Commentary

Amedysis Reports 1Q Prelim Earnings

Apr 26, 2013

Zacks Rank #1 Addition for Thursday

Apr 18, 2013

DaVita Hit 52-Week High

Apr 03, 2013

Zacks #1 Rank Additions for Friday

Dec 07, 2012

Zacks #1 Rank Additions for Monday

Oct 01, 2012

Zacks #1 Rank Additions for Monday

Aug 27, 2012

Stock Market News for August 2, 2012

Aug 02, 2012

Report for CO

May 31, 2013

More CO Zacks Commentary

Financials

EPS TTM	0.24
Sales	60
Net Income	19
Price/Earnings	11.96
Price/Book	0.98
Price/Cash Flow	8.20
Price/Sales	2.67

More CO Financials

News

China Cord Blood Corporation Reports Financial Results for the Fourth Quarter and Full Year of Fiscal 2013 - Pr Newswire

Jun 18, 2013

Earnings Scheduled For June 18, 2013 - Benzinga

Jun 18, 2013

Weekly Preview: Fed In Focus as Tapering Fears Mount - Benzinga

Jun 14, 2013

China Cord Blood Corporation to Report Fourth Quarter and Full Year of Fiscal 2013 Financial Results - Pr Newswire

Jun 11, 2013

A Steady Growth Outlook Is Not Fully Reflected in This Company`s Share Price - TheMotleyFool

Jun 6, 2013

China Cord Blood is Among the Companies in the Health Care Services Industry With the Highest Operating Margin (CO, CCM, LH) - Financial News Network Online - News Corner

May 29, 2013

Canadian Orebodies Announces Adoption of Advance Notice By-Law - Marketwire

May 22, 2013

Canadian Orebodies Announces Adoption of Advance Notice By-Law - Marketwire Canada

May 22, 2013

See All News Stories on CO

Broker Recommendations

Current ABR	1.00
ABR (Last Week)	1.00
# of recs in ABR	1
Average Target Price	5.50
Industry Rank by ABR	178 out of 265
Rank in Industry	5 out of 16

More CO Broker Recommendations

Day Low - High	2.86 - 2.91
52wk Low - High	2.21 - 3.20
Previous Close	2.87
Avg. Volume	61,097
Industry	MED-OUTP/HM CRE
Market Cap	209.52 M
Div - Yield	0.00 - 0.00
Beta	0.32
P/E (F1)	13.67
Current Year Est.	0.21
Quarterly Earnings ESP	NA

P/E (F1)	13.67
PEG Ratio	NA
Current Year Est.	0.21
Current Quarter Estimate	0.02
Most Accurate Estimate	NA
Earnings ESP	NA
Next Earnings Report Date	06-18-2013
EPS Last Year	0.24
Expected Earnings Growth	NA

Username: Password:

Remember me [?]

China Cord Blood Corp: (NYSE: CO)

$2.91

0.04 (1.39%)

Volume 135,288

Jun 18 04:01 PM ET

Stock Activity

Premium research

Zacks Rank Short-Term: 1-3 Months

Zacks Recommendation Long-Term: 6+ Months

Zacks Industry Rank

Equity Research Report

Key Earnings Data

Company Description